KMT2A and leukemia: The differential antiproliferation activities of compound 1 is consistent with its ability to suppress DOT1L/H3K79 methylation and SEC regulated gene expression, which are critical to MLL-r leukemia and Myc-driven blood cancer, but largely dispensable to other solid tumor cells.